E
Enrico Derenzini
Researcher at European Institute of Oncology
Publications - 123
Citations - 3138
Enrico Derenzini is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 28, co-authored 107 publications receiving 2570 citations. Previous affiliations of Enrico Derenzini include University of Texas MD Anderson Cancer Center & University of Bologna.
Papers
More filters
Journal ArticleDOI
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Francesco Passamonti,Chiara Cattaneo,Luca Arcaini,Riccardo Bruna,Michele Cavo,Francesco Merli,Emanuele Angelucci,Mauro Krampera,Roberto Cairoli,Matteo G. Della Porta,Nicola Stefano Fracchiolla,Marco Ladetto,Carlo Gambacorti Passerini,Marco Salvini,Monia Marchetti,Roberto M. Lemoli,Alfredo Molteni,Alessandro Busca,Antonio Cuneo,Alessandra Romano,Nicola Giuliani,Sara Galimberti,Alessandro Corso,Alessandro Morotti,Brunangelo Falini,Atto Billio,Filippo Gherlinzoni,Giuseppe Visani,Maria Chiara Tisi,Agostino Tafuri,Patrizia Tosi,Francesco Lanza,Massimo Massaia,Mauro Turrini,Felicetto Ferrara,Carmela Gurrieri,Daniele Vallisa,Maurizio Martelli,Enrico Derenzini,Attilio Guarini,Annarita Conconi,Annarosa Cuccaro,Laura Cudillo,Domenico Russo,Fabrizio Ciambelli,Anna Maria Scattolin,Mario Luppi,Carmine Selleri,Elettra Ortu La Barbera,Celestino Ferrandina,Nicola Di Renzo,Attilio Olivieri,Monica Bocchia,Massimo Gentile,Francesco Marchesi,Pellegrino Musto,Augusto B. Federici,Anna Candoni,Adriano Venditti,Carmen Fava,Antonio Pinto,Piero Galieni,Luigi Rigacci,Daniele Armiento,Fabrizio Pane,Margherita Oberti,Patrizia Zappasodi,Carlo Visco,Matteo Franchi,Paolo Grossi,Lorenza Bertù,Giovanni Corrao,Livio Pagano,Paolo Corradini +73 more
TL;DR: This study adds to the evidence that patients with haematological malignancies have worse outcomes and the general Italian population with COVID-19 has high mortality, by calculating standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates.
Journal ArticleDOI
Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Pier Luigi Zinzani,Gerardo Musuraca,Monica Tani,Vittorio Stefoni,Enrica Marchi,Mariapaola Fina,Cinzia Pellegrini,Lapo Alinari,Enrico Derenzini,Antonio De Vivo,Elena Sabattini,Stefano Pileri,Michele Baccarani +12 more
TL;DR: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
Journal ArticleDOI
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Pier Luigi Zinzani,Filippo Venturini,Vittorio Stefoni,Mariapaola Fina,Cinzia Pellegrini,Enrico Derenzini,Letizia Gandolfi,Alessandro Broccoli,Lisa Argnani,Federica Quirini,Stefano Pileri,Michele Baccarani +11 more
TL;DR: In the experience, gemcitabine proved to be effective in pretreated MF and PTCLU patients, even in the long term.
Journal ArticleDOI
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
Pier Luigi Zinzani,Vittorio Stefoni,Monica Tani,Stefano Fanti,Gerardo Musuraca,Paolo Castellucci,Enrica Marchi,Mariapaola Fina,Valentina Ambrosini,Cinzia Pellegrini,Lapo Alinari,Enrico Derenzini,Giancarlo Montini,Alessandro Broccoli,Francesco Bacci,Stefano Pileri,Michele Baccarani +16 more
TL;DR: The results confirm FDG-PET as a valid tool for follow-up of patients with HL and NHL and in patients with inconclusive positive results, histologic confirmation plays an important role in identifying true relapse.
Journal ArticleDOI
Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Pier Luigi Zinzani,Cinzia Pellegrini,Letizia Gandolfi,Vittorio Stefoni,Federica Quirini,Enrico Derenzini,Alessandro Broccoli,Lisa Argnani,Stefano Pileri,Michele Baccarani +9 more
TL;DR: Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidOMide maintenance.